Long-term follow-up of people with hepatitis B treated with imdusiran
Follows adults with chronic hepatitis B who previously received imdusiran and remain off therapy.
Plain-language title generated from the registry record
Registry title: Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
Key facts
- Where
- Cardiff and London, United KingdomSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 70 years old?
Source: NCT06277037, who can take part
Where in United Kingdom
- University Hospital of Wales, CardiffCardiff, United KingdomNot yet recruiting
- King's College HospitalLondon, United KingdomNot yet recruiting
- Royal London HospitalLondon, United KingdomNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Arbutus Biopharma Corporation
- Trial code
- NCT06277037
- Record updated
- 27 November 2024
- Original description
This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study [EOS] visit) from their imdusiran clinical trial (the "parent study"). No interventions will be performed in this study other than blood sample collections, review of current medications, and reporting of any adverse events related to study procedures or NA therapy if restarted. Study participation will be for approximately 2 years (to complete a total of at least 3 years of follow-up while off NA therapy, inclusive of parent study participation).Read full original descriptionShow less
A Long-Term Follow-up Study for Subjects With Chronic Hepatitis B Previously Treated With Imdusiran (AB-729)
This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study [EOS] visit) from their imdusiran clinical trial (the "parent study"). No interventions will be performed in this study other than blood sample collections, review of current medications, and reporting of any adverse events related to study procedures or NA therapy if restarted. Study participation will be for approximately 2 years (to complete a total of at least 3 years of follow-up while off NA therapy, inclusive of parent study participation).
Inclusion: Have participated in a prior imdusiran clinical trial,; Have discontinued NA therapy in that trial and remain off NA therapy,; Have completed less than 3 years of follow-up visits after NA discontinuation in the parent study; Have the ability to review and provide signed informed consent which includes compliance with all protocol-specified visit schedules and requirements.
Exclusion: Not applicable.